Services on Demand
- Cited by SciELO
- Access statistics
Jornal de Pediatria
Print version ISSN 0021-7557On-line version ISSN 1678-4782
CASTRO, Ana Paula Beltran Moschione. Calcineurin inhibitors in the treatment of allergic dermatitis. J. Pediatr. (Rio J.) [online]. 2006, vol.82, n.5, suppl., pp.S166-S172. ISSN 0021-7557. http://dx.doi.org/10.1590/S0021-75572006000700006.
OBJECTIVE: To review the role of calcineurin inhibitors in the treatment of allergic dermatitis, focusing on mechanisms of action, efficacy and topical and systemic adverse effects. SOURCES: Articles written in English and published in MEDLINE using the following keywords: pimecrolimus, tacrolimus, calcineurin inhibitors. Original articles that presented controlled and open studies for assessing efficacy, tolerability and adverse effects were selected. Review articles and case series were also evaluated; the latter was only considered for assessing adverse effects. The official websites of the Food and Drug Administration and of manufacturers of calcineurin inhibitors were also used. SUMMARY OF THE FINDINGS: The data showed that calcineurin inhibitors are efficient in the treatment of mild to severe atopic dermatitis, leading to improvement in symptoms, reduction in number of attacks and need of topical corticotherapy. Calcineurin inhibitors have good tolerability and few topical adverse effects. To date, there has been no evidence to support higher prevalence of neoplasia in patients using these drugs; however, an adequate pharmacovigilance system has been set up to assess this aspect. CONCLUSIONS: Calcineurin inhibitors, which are a new drug class in the treatment of allergic dermatitis, are efficient, well tolerated and have few adverse effects. Calcineurin inhibitors should always be used according to recommended guidelines, and patients should always be followed by the physician during and after their administration.
Keywords : Pimecrolimus; tacrolimus; calcineurin inhibitors.